| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5318 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2769 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1666 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1333 | 2021 |
| Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (9), 2348-2361. e6, 2021 | 1130 | 2021 |
| Antibody status and incidence of SARS-CoV-2 infection in health care workers SF Lumley, D O’Donnell, NE Stoesser, PC Matthews, A Howarth, ... New England Journal of Medicine 384 (6), 533-540, 2021 | 981 | 2021 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell, 2022 | 911 | 2022 |
| Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum C Liu, HM Ginn, W Dejnirattisai, P Supasa, B Wang, A Tuekprakhon, ... Cell 184 (16), 4220-4236. e13, 2021 | 751 | 2021 |
| Antibody evasion by the P. 1 strain of SARS-CoV-2 W Dejnirattisai, D Zhou, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (11), 2939-2954. e9, 2021 | 658 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 589 | 2021 |
| Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum A Tuekprakhon, R Nutalai, A Dijokaite-Guraliuc, D Zhou, HM Ginn, ... Cell 185 (14), 2422-2433. e13, 2022 | 579 | 2022 |
| Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (8), 2201-2211. e7, 2021 | 488 | 2021 |
| The antigenic anatomy of SARS-CoV-2 receptor binding domain W Dejnirattisai, D Zhou, HM Ginn, HME Duyvesteyn, P Supasa, JB Case, ... Cell 184 (8), 2183-2200. e22, 2021 | 355 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 331 | 2021 |
| Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison M Ainsworth, M Andersson, K Auckland, JK Baillie, E Barnes, S Beer, ... The Lancet Infectious Diseases 20 (12), 1390-1400, 2020 | 317 | 2020 |
| A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1β, TNF-α and IL-6 challenges in C57BL/6 mice DT Skelly, E Hennessy, MA Dansereau, C Cunningham PloS one 8 (7), 2013 | 306 | 2013 |
| Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study DW Eyre, SF Lumley, D O'Donnell, M Campbell, E Sims, E Lawson, ... eLife 9, e60675, 2020 | 274 | 2020 |
| Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine RP Payne, S Longet, JA Austin, DT Skelly, W Dejnirattisai, S Adele, ... Cell 184 (23), 5699-5714. e11, 2021 | 270 | 2021 |
| Antibody testing for COVID-19: a report from the National COVID Scientific Advisory Panel ER Adams, M Ainsworth, R Anand, MI Andersson, K Auckland, JK Baillie, ... Wellcome Open Research 5, 2020 | 222 | 2020 |
| Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern DT Skelly, AC Harding, J Gilbert-Jaramillo, ML Knight, S Longet, A Brown, ... Nature Communications 12 (1), 1-12, 2021 | 208* | 2021 |
